Fig. 6
From: DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment
In vivo, DRP2 deficiency inhibits lung adenocarcinoma progression. (A) Schematic diagram of an animal model of LUAD cells. (B–D) Tumor growth and weight were monitored in mice. (E) Immunohistochemical staining was performed to detect the expression of DRP2, PCNA and ki 67 in the xenografts of two groups of nude mice. (F) Left section: Photograph of a mouse lung with metastatic nodules after inoculation with sh-NC or sh-DRP2-2 A549 cells. Scale bar = 3 mm. Right section: Representative microscopic image of H&E staining from the established micrometastases in the lungs of the pair of mice mentioned in the left section. Scale bar = 1 mm. Red arrows indicate metastatic nodules and micrometastases in the lung. (G,H) Dot plots showed differences in metastatic nodules (G) and micrometastases (H) in lung tissue between DRP2 silenced group and control group (4 per group). Data were expressed as mean ± standard deviation (SD, n = 4). **P < 0.01, ***P < 0.001 versus “sh-NC” group.
